dan

shedtwt, anti-fatphobic, pro-recov

[dan @DanBeebug75]

PINNING THIS TO STAY MOTIVATED!!! TRYING TI LOSE WEIGHT BEFORE AUGUST 10TH so i can be skinny before i go back to school. gw- 130, gw2- 120

[dan @DanBeebug75]

@SoSoValueCrypto

SoSo Crypto Daily | Crypto Market Steady in Recovery; Regulatory Developments and Institutional Innovation Signal Shifting Landscape

🎧 Tap to listen｜Catch up on key market shifts and what’s really driving them: https://t.co/0Lyimnofic

[dan @DanBeebug75]

@rogueiq nice AMA :D

[dan @DanBeebug75]

* I want to build a friendship that feels like home �� If you’re warm, kind, and funny—let’s start ��

[dan @DanBeebug75]

@nguyntu97536762 @BioProtocol France's recent legalization of cannabis-based medicines is a breakthrough moment.

[nguyễn tuấn @nguyntu97536762]

GM @BioProtocol
Below is a detailed analysis of the legal landscape, opportunities, and challenges in three to five key European countries — Germany, the Netherlands, Poland, and France — in relation to New Leaf DAO's Research Focus Areas (chemical profiling, efficacy testing for pain/Parkinson’s, and development of medical cannabis products). These countries were selected based on varying levels of regulatory openness to illustrate the range of feasible entry paths:
Germany
Legal & Regulatory Framework

The Cannabisgesetz (CanG) law, effective from April 1, 2024, has removed cannabis from the strict narcotics schedule (Narcotic Drugs Act) for certain purposes, and allows production/use of cannabis for medical and research purposes.
The MedCanG (Medical Cannabis Act) portion of this law governs the supply of cannabis for medical & scientific use.
New regulations simplify certain prescription & dispensing procedures: prescriptions for patients under statutory health insurance are valid for up to 28 days; private prescriptions can be longer. Doctors are granted expanded rights to prescribe directly, reducing bureaucracy if they have the necessary professional certification.
However, there is a draft bill proposed by the government to tighten some aspects such as restricting delivery of medication by mail, requiring patients to have in‑person consultations before prescriptions, etc.

Opportunities

Germany is a large market with strong research and clinical trial infrastructure, many research institutes, and high‑quality chemical analysis labs — favorable for chemical profiling, preclinical / clinical trials.

The conditional legalization of medical cannabis reduces legal risk compared to many other countries.

A domestic market plus export to other EU countries are possible if products meet standards (e.g. GMP, GLP, certifications, etc.).

Simplified prescription & drug dispensing help reach patients more quickly.

Challenges / Risks

Licensing/approval processes are still strict; the cost to meet GMP standards, stability testing, safety is high.

Policy volatility: as shown by draft amendments, there may be new constraints (e.g. requirement for in‑person visits, restrictions on mail delivery of prescriptions).

Competition from domestic companies & large players in medical cannabis; pressure on price; economies of scale matter.

Health insurance reimbursement could be a barrier if the drug is not widely recognized or lacks sufficient clinical data.

The Netherlands

Legal & Regulatory Framework

Medical use: medical cannabis is supplied at pharmacies by prescription — regulated by the Opium Act + Medicines Act.

For research / chemical analysis / scientific experimentation, research units, hospitals, etc., can apply for an “opium exemption permit” to engage in cultivation, production for medical / analytical purposes.

Strict quality requirements are in place, in accordance with EU regulations as well as national drug/medicines laws. Although medical cannabis is not fully registered as a “new medicinal product” with the European Medicines Agency (EMA), it must still meet medicinal‑type quality standards, particularly regarding impurities, analytical testing.

Opportunities

The Netherlands has a long tradition of medical cannabis research and experimentation, with relatively good access to markets & supply chain.

The regulatory system and pharmaceutical infrastructure are relatively well‑defined — favorable for projects involving chemical profiling, efficacy testing.

Societal acceptance is higher compared to many other countries; there's practical experience in providing medical cannabis.

Opportunity to partner with Dutch research organizations & pharmaceutical companies to develop special strains or formulations with strong efficacy.

Challenges / Risks

Even though permitted, for a product to be approved as a full “medicinal product,” it often must go through many steps, including clinical trials (if one wants insurance coverage or reimbursement) — which implies high cost and long time.

Issues of batch‑to‑batch consistency & impurity control (heavy metals, pesticide residues, etc.) are extremely important.

Product costs tend to be high, especially if importing or producing domestically under strict GMP conditions.

Limitations if the product contains high THC or is in more traditional forms such as flower, if the law/distribution channels are not yet fully accommodating.

Poland

Legal & Regulatory Framework

Poland has allowed medical cannabis since 2017; patients can purchase medical cannabis (in dried form / extracts) at pharmacies via prescription.

Herbal material / raw medical ingredients (herbs, resin, extracts) are viewed as pharmaceutical raw materials and must be used in pharmacy compounding — production and distribution must comply with pharmaceutical law.

Import plays a large role because there is limited domestically licensed cultivation or production at scale.

New laws are under discussion to tighten certain points: for instance, limiting prescriptions via telemedicine, requiring in‑person consultations for medical cannabis prescriptions.

Opportunities

The medical cannabis market in Poland is growing very rapidly: imports and number of prescriptions are increasing significantly.

Market costs may be relatively lower than in Germany, because the market is smaller and competition is less — if New Leaf DAO’s research is of good quality, there is potential to capture good market share.

Opportunity to provide high‑quality strains, clearly characterized chemical profiles, and to support preclinical / clinical data for indications such as chronic pain, Parkinson’s disease, if proven.

Challenges / Risks

Domestic production is not strong yet; heavy reliance on imports → high costs, dependence on foreign sources.

New regulatory proposals may make prescribing more restrictive — requiring in‑person visits may reduce convenience and slow patient access.

High costs & time required to demonstrate clinical efficacy if one wants expanded indications & insurance coverage.

Institutions for strain development, testing in country may lack consistent capacity or standardization to ensure a stable chemical profile across batches.

France

Legal & Regulatory Framework

Previously, production, import, distribution, and use of cannabis & THC were banned under the Public Health Code—but recently there has been a change: law No. 2023‑1250 (dated December 26, 2023) allows production, importation & distribution of cannabis‑based medicines for medical purposes, with a temporary 5‑year license issued by ANSM.

A medical cannabis pilot program has been underway since 2021, involving thousands of patients, to assess effects on pain, spasms, quality of life, etc.

France is in the process of adopting comprehensive regulatory texts for cannabis‑based medicines, including domestic production, distribution, testing, certification, pharmacovigilance. Regulatory draft texts have been submitted to the European Commission for evaluation.

Opportunities

Once the regulatory framework is completed (assuming approval by the European Commission), France will be a large & important market, with a strong healthcare system and many patients needing treatments for chronic pain, Parkinson’s, etc.

Having a 5‑year temporary license for cannabis‑based medicines allows companies to test products, develop strains, study efficacy under real‑world conditions.

Enhancing domestic production capacity, if licensure is granted, will reduce import costs and improve quality control.

Opportunity for international collaboration, and exporting into France if products meet European standards.

Challenges / Risks

There are still many legal uncertainties: how many strains will be accepted, what levels of THC will be allowed, what forms of use (flower, extract, oil), how distribution (pharmacies, hospitals), and reimbursement from insurance will work.

High requirements for proving efficacy / clinical data, especially for chronic pain, Parkinson’s.

The authorization process with ANSM + evaluation by the European Commission may take a significant amount of time, and be costly.

Possible pushback from public opinion / political spheres if products are perceived as having abuse potential or psychoactive risks.
$BIO
@newleaf_finance #DeSci #BioProtocol

[dan @DanBeebug75]

@nguyntu97536762 @BioProtocol Proud to see this from a fellow Vietnamese. ����

[nguyễn tuấn @nguyntu97536762]

GM @BioProtocol
Introduction & Objectives

New Leaf DAO is a decentralized investment platform focused on the medical cannabis market.
The core idea is to tokenize premium real-world cannabis assets, making value creation transparent and accessible for patients, investors, doctors, and regulators.
They integrate blockchain and artificial intelligence (AI) to improve the efficiency of management, research, and operations within the medical cannabis industry.

Market & Hypothesis

According to the project's forecasts:

Sales of pre-roll cannabis products are expected to reach $4.1 billion USD by 2024.

Infused pre-rolls (combining flower and concentrates) are projected to generate approximately $1.75 billion USD in revenue in 2024.

The project emphasizes that medical cannabis research is currently fragmented and lacks standardization.
New Leaf aims to accelerate this process by supporting open research and turning scientific findings into community-owned assets.

Research & Applications
New Leaf plans to carry out a range of medical and scientific studies, including:

Phytochemical profiling of proprietary cannabis strains to identify cannabinoids, terpenes, flavonoids, and other compounds.

Studying the analgesic efficacy (pain relief potential) of analyzed cannabis strains to identify promising treatments for headaches, migraines, and chronic pain.

Research on Parkinson’s symptoms, testing a unique strain identified for anti-inflammatory and neuroprotective properties to see if it can reduce Parkinsonian symptoms.

Team & Community

The project features individuals with experience in corporate law, finance, blockchain, healthcare, and the cannabis industry.

They are also actively inviting community participation through channels like Discord and Telegram.

Roadmap

TimeframeKey ActivitiesQ4 2025Pilot & validation phase — launch of medical pre-roll production in CanadaQ1 2026Scale-up production, commercialization, and contract manufacturingQ2 2026Expand partnerships, licensing deals, and strategic joint venturesS2 2026Product innovation, international expansion, export and multi-country distribution

Value Model & Benefits
Once New Leaf’s token launches, investors will gain exposure to an enterprise value of approximately $25 million USD in premium cannabis assets managed by the project.
Tokenizing real-world assets enables the distribution of value among multiple stakeholders — including patients, investors, doctors, and regulators — with greater transparency in governance.
Key Considerations & Risks
Legal & Regulatory Risk: Medical cannabis is highly sensitive in many countries. Regulatory changes could significantly impact the project's operations and value.
Scientific Validation: While the project plans research, achieving clinical-grade validation recognized by healthcare authorities remains a major challenge.
Liquidity & Token Market: Tokenizing real-world assets requires a clear market structure, liquidity, and regulation to avoid risks for investors.

Competition & Technical Risk: Competing blockchain or scientific projects in similar domains may create competitive pressure.

$BIO @newleaf_finance

[dan @DanBeebug75]

Let’s follow and support each other! I’ll follow you back! ��

[nguyễn tuấn @nguyntu97536762]

GM @BioProtocol
🧠 What is Nootropics DAO?

Nootropics DAO is a BioDAO within the BIO ecosystem, focusing on the research, development, and commercialization of cognitive enhancers / nootropics.

Its goal is to bring together professional researchers, citizen scientists, and biohackers to build an open ecosystem for collaborative research and product development.

📊 Market & Potential

The current market for chemical nootropics and brain health supplements is estimated at around $10 billion, expected to exceed $20 billion by 2034.

The total addressable market for cognitive enhancers (pharmaceuticals, supplements, herbal products, etc.) is estimated at approximately $100 billion.

🚀 Roadmap Highlights
TimeKey MilestonesQ1 2025Launch of the $NDT token via BIO Protocol; introduction of "Noot Social" – a social platform for citizen science.Q2 2025Launch of “Nexus Knowledge Base”; cognitive testing tools and N=1 self-experiments; community governance for research initiatives.Q4 2025First tokenized IP launch: a novel formula combining biological peptides and natural extracts.
💡 Value Capture Model
The project aims to generate real-world value through:
Commercial Activities: Producing and distributing nootropics in partnership with suppliers and existing product lines.
Research & IP Licensing: Developing new formulas, obtaining patents or licensing proprietary compounds and experiences.

Community-Driven Data: Leveraging N=1 self-experiments and community feedback to drive iterative product improvement.

⚠️ Strengths & Risks

Strengths:

Attractive theme with a large and growing market (brain health, cognitive performance).

Integration of research, community engagement, and commercialization – more than just a concept.

Part of the DeSci (Decentralized Science) movement via BIO Protocol, with clear launchpad and governance mechanisms.

Risks:

Regulatory sensitivity: Nootropics may fall into gray legal areas depending on the country (drugs vs. supplements vs. research compounds).

Efficacy and safety: Requires clinical validation and scientific evidence to ensure safety and effectiveness.

Highly competitive: The cognitive enhancer market is crowded with established players and brands.

Complex tokenized IP model: Monetization and licensing of intellectual property can be challenging and require transparency and solid governance.
@NootropicsDAO_ $BIO

[dan @DanBeebug75]

@spacecoin
https://t.co/JufPszpOyF

[Spacecoin™ 🛰️ @spacecoin]

🛰️Fresh out of KBW2025, we are excited to share a roadmap reveal: Starmesh, the Virtual Satellite Network (VSN) that gives you the privacy and safety you deserve when accessing the Internet.

While we build out our broader physical satellite internet infra, you'll first be able to use Starmesh to browse the web with ultra privacy, and tap into decentralized services like data storage on @WalrusProtocol and DeFi on @Creditcoin

[dan @DanBeebug75]

weighed my lowest of 128 on march 28th and now its june 27th and im 136

[dan @DanBeebug75]

got locked out of my account for a few days

[dan @DanBeebug75]

@ibyaerii ATEEE

[dan @DanBeebug75]

@weestsidexx whyd they bring bts into this

[dan @DanBeebug75]

@Bri_Star3 POOR BABY

[Bri⁷༄ @Bri_Star3]

How the fuck has he done that then

[dan @DanBeebug75]

im gonna starve so hard trust me by the end of the summer i will be thin

[dan @DanBeebug75]

back up to 140 KMS KMSKMS

[dan @DanBeebug75]

i quit the job i had for three days

[dan @DanBeebug75]

@Ares1336 i got retriggered ngl

[dan @DanBeebug75]

i feel like such a fucking fatass i hate my life :/ and i wanna lose weight NEOW i know i just have to be consistent but i hate myself sm